Who markets Seroquel?
Seroquel is the brand name for quetiapine and is marketed by Bristol‑Myers Squibb (BMS) in the United States. BMS acquired the rights when it bought Celgene in 2019; Celgene originally launched the drug in 1999.
Where did the brand begin?
Celgene, founded in 1986 as a biopharmaceutical company, developed quetiapine and brought Seroquel to market in 1999. The launch was supported by a series of patents covering the compound, its formulations, and its uses for schizophrenia and bipolar disorder.
When did the original patents expire?
Most of the core patents filed in the mid‑1990s expired by the mid‑2010s. Generic quetiapine entered the U.S. market in 2015, after patent protection had ended. Current patents listed on DrugPatentWatch cover limited aspects such as specific dosage forms or delivery methods and have long expiration dates.
Can generic quetiapine be found today?
Yes. Generic quetiapine is available in several strengths and dosage forms from multiple manufacturers, including Teva, Mylan, and Sandoz. Because the key patents have expired, many pharmacies now dispense the generic version at a lower cost.
Which companies produce generic quetiapine?
Major generic producers include:
- Teva – one of the largest U.S. generic manufacturers, offering 25 mg and 100 mg tablets.
- Mylan – supplies 25 mg and 50 mg tablets and has a broad distribution network.
- Sandoz – provides a range of strengths and has been expanding its generic portfolio.
Other smaller specialty manufacturers also offer quetiapine tablets, but the three above dominate the U.S. market.
Are there any biosimilars or alternative treatments on the horizon?
Quetiapine is a small‑molecule drug, so biosimilars do not apply. Competitors include other atypical antipsychotics such as Risperdal (risperidone), Abilify (aripiprazole), and newer agents like Lumakras (sotorasib) for different indications. None of these are direct generics of quetiapine but serve similar patient populations.
Does Seroquel have any ongoing patent disputes?
DrugPatentWatch shows no major active patent litigation for the brand name itself. Generic manufacturers have obtained patent licenses where required, and no significant disputes have surfaced in recent years.
What’s the difference between brand‑name and generic quetiapine?
Both contain the same active ingredient (quetiapine fumarate) and deliver identical therapeutic effects when taken as directed. The brand name typically offers a broader marketing claim and a longer period of market exclusivity. The generic versions are chemically identical but may differ in inactive excipients and packaging, which can affect cost and patient preference.
When can patients expect continued brand availability?
BMS maintains the Seroquel brand, and no scheduled expiration of the brand‑specific trademarks or patents is publicly anticipated. The brand will remain available as long as BMS continues to market it.
Why might a patient choose one over the other?
Patients often select the generic for cost savings. Others may prefer the brand if they perceive better efficacy, have had a prior positive experience, or if the brand’s dosing schedule is more convenient.
Where can I find detailed patent status?
DrugPatentWatch offers a searchable database that lists current and expired patents for quetiapine, including filing dates, claim details, and expiration dates. The database is useful for developers, pharmacists, and investors monitoring the competitive landscape.
Key takeaway
Seroquel is a brand name for quetiapine owned by Bristol‑Myers Squibb, originally developed by Celgene. Most core patents have expired, enabling a robust generic market, but the brand remains available for patients who prefer it.